NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
32 trialsNCT05691504 2026-03-19
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04302025 2026-03-06
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07449754 2026-03-04
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
Phase 2 Recruiting
NCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT04409639 2026-02-12
CONCERTO
University of Utah
Phase 2 Active not recruiting
NCT04835805 2026-02-03
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
Phase 1 Active not recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04109456 2026-01-15
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03202316 2025-12-16
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT05034627 2025-11-28
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT03175432 2025-11-03
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03600701 2025-10-07
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03202940 2025-09-25
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT04079179 2025-09-18
NACHO-COBI
Baylor College of Medicine
Phase 2 Recruiting
NCT05441514 2025-09-16
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed